跳至主要内容
临床试验/NCT01213667
NCT01213667Unknown4 期

Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations

University of Cologne1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
110
试验地点
1
主要终点
Visual acuity

研究概览

简要总结

To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • active subfoveal CNV related to exudative age-related macular degeneration (all subforms)
  • age > 60 years
  • visual acuity > 20/400
  • no previous treatment for AMD

排除标准

  • any previous AMD therapy
  • other CNV types (myopic, parapapillary)
  • contraindication for ranibizumab treatment
  • prior study participation for AMD
  • pregnancy / premenopausal women

研究组 & 干预措施

ranibizumab as needed

Other

干预措施: Ranibizumab (Drug)

结局指标

主要结局

Visual acuity

时间窗: 2 years

Change in visual acuity within the observation period

次要结局

  • Changes in OCT central retinal thickness / retinal volume(2 years)
  • Association between treatment application delay and visual outcome(2 years)
  • Association between re-treatment necessity / frequency and intraocular cytokine profiles(2 years)
  • Association between treatment response and genotype(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Philipp S. Muether

MD, PhD

University of Cologne

研究点 (1)

Loading locations...

相似试验